Profile cover photo
Profile photo
Oncotheis
Oncotheis
Oncotheis
About
Oncotheis's posts

Post is pinned.Post has attachment
Public
On May 19-24, 2017
OncoTheis is participating to the American Thoracic Society (ATS) International conference in Washington. Meet us at our booth (#1529) to discover our last developments in 3D in vitro oncology research !

Post has attachment
On November 16-17, 2017
OncoTheis is participating to the CAAT Academy Workshop dedicated to In Vitro Lung Models in Geneva, Switzerland.
Among many topics, OncoTheis will present its in vitro 3D tissue model and assays to detect lung carcinogenesis.

Post has attachment
On June 12-16, 2017
Oncotheis will present its genetically engineered human lung cancer model @ the World Preclinical Congress in Boston. Join us @ booth #602 !
http://www.worldpreclinicalcongress.com/
Photo

Post has attachment
On April 27, 2017
OncoTheis won the Run4Science 2017 Special Jury Award to develop in vitro models for immuno-oncology !

The Run4Science association aims to reduce animal experimentation by promoting alternative research methods and encouraging their use by the scientific community. Funds for projects are raised thanks to an annual fun run and through sponsorship. Next run: June 11, 2017 ! https://www.run4science.ch/

Post has attachment
On March 1st, 2017
Oncotheis human genetically engineered in vitro models for lung cancer presented @ The NC3Rs Cancer Research Workshop, 1-2 March 2017; London.
https://www.nc3rs.org.uk/events/workshop-human-tissue-models-cancer-research
Photo

Post has attachment
On February 22, 2017
From Small molecule to Oncolytic virus: OncoTheis presents OncoCilAir™, in vitro testing platform for human lung cancer @ 3D Cell Culture, London.
http://www.smi-online.co.uk/pharmaceuticals/uk/3D-Cell-Culture
Photo

Post has attachment
On February 10, 2017
Last year PETA praised Swiss biotech Oncotheis Sarl for its in vitro cell cultures that can be used as replacements for experiments on animals:

Post has attachment
On January 24, 2017
New year, new model. The OncoCilAir EGFRdel19 model from OncoTheis mimics in vitro Non Small Cell Lung Cancer with EGFR mutation. 
Photo

Post has attachment
On March 12-16, 2017
OncoTheis will present "Genetically Engineered 3D In Vitro Human Airway Model Sensitive to Carcinogens" @ the 56th annual meeting of the Society of Toxicology in Baltimore: 

Post has attachment
Geneva, Switzerland - November 16, 2016. Dr Samuel Constant, OncoTheis CEO and Epithelix COO, honoured by the Faculty of Science.

In the frame of the Entrepreneurship Week, Dr. Samuel Constant received from Professor Jérôme LACOUR, Dean of the Faculty of Science, the “Prix Jaubert” rewarding his career and the creation of two successful companies, Epithelix Sàrl and OncoTheis Sàrl. The spirit of the prize is to recompense the outstanding work of a chemist oriented towards the well-being of humanity.

Epithelix, founded in 2006, provides alternative in vitro solutions to animal experimentation for evaluating the effects of drugs in development and assess the toxicity of chemical compounds on the human respiratory tract (www.epithelix.com).

OncoTheis, founded in 2014, is dedicated to developing innovative human bioengineered tissues and organoids for cancer research (www.oncotheis.com).

We are proud to share these exciting scientific and entrepreneurial adventures with a recognized, experimented and creative leader: congratulations Sam!

Photo
Wait while more posts are being loaded